Liquidia Corp (LQDA)
AI stock analysis · as of Jun 21, 2026
Loading microstructure…
Liquidia is a small-cap commercial-stage biopharma that just launched YUTREPIA (inhaled treprostinil) in June 2025 into the ~100k-patient PAH/PH-ILD market, with L606 as a pipeline follow-on. Revenue scaled from $14M (2024) to $158M (2025) on the partial launch, and the stock has 6x'd off 52-week lows to $71 (near highs at $73). The core investment question is whether YUTREPIA's commercial ramp and label expansion can sustain a ~$6.3B market cap that already prices in aggressive uptake — against the existential risk of United Therapeutics' litigation to pull YUTREPIA's 505(b)(2) approval.
valuationExpensive on trailing metrics (P/S 21.9, P/B 57.8, EV/EBITDA 134.7) but more defensible on forward P/E of ~12.8 if 2026 YUTREPIA ramp meets expectations — the stock prices in successful litigation defense and strong commercial execution.
This analysis is from Jun 21, 2026. Want the latest on LQDA, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Explosive revenue inflection: 2025 revenue of $158M vs. $14M in 2024 (>10x), driven by half a year of YUTREPIA sales, with gross margin expanding to 91.6%
- · Clinically differentiated profile: YUTREPIA titrates to 291.5 mcg QID vs. 64 mcg for Tyvaso DPI, addressing dose-limited patients in a 100k+ U.S. patient market
- · Multiple expansion paths: label expansion into PH-COPD, IPF, PPF, SSc-RP, plus L606 global Phase 3 in PH-ILD with twice-daily dosing and 7.3x lower Cmax
- · Forward P/E of ~12.8 is surprisingly modest if YUTREPIA ramps as expected, implying the Street already models meaningful 2026 earnings
- · Strong institutional ownership (70.2%) and Q1 earnings beat indicate professional conviction; shareholders broadly backed management at annual meeting
- · Elevated short interest (13.9% of float, 6.05 days to cover) sets up potential squeeze dynamics on positive catalysts
Bear case
- · United Therapeutics litigation seeking to withdraw YUTREPIA's FDA approval is an existential, binary risk — an adverse ruling effectively zeros the core asset
- · Valuation is stretched on backward-looking metrics: P/S of 21.9, P/B of 57.8, EV/EBITDA of 134.7, and trailing P/E of 418 — the stock is priced for near-flawless execution
- · Stock sits at $71 vs. analyst mean target of $66.13, i.e. trading ~7% above consensus with limited upside even in the Street's view
- · Concerning insider/institutional selling per news flow: director sold ~$14M, HR chief sold ~25k shares under 10b5-1, Canaan sold 196k shares — at multi-year highs
- · HCR Revenue Interest Financing Agreement amended six times through 2025 signals covenant stress; debt/equity of 170 and only $190M cash vs. $198M debt with -$42M FCF
- · Supply chain fragility: single-source dependence on LGM (API), Plastiape (device), Lonza (encapsulation); CADD-MS 3 pump discontinuation already constrains the legacy Treprostinil Injection stream
- · Newly launched product with unproven payer coverage, formulary access, and durable physician adoption at scale
Catalysts
- · Resolution of United Therapeutics litigation — the dominant binary catalyst
- · Next earnings on August 12, 2026 — first read on full-year YUTREPIA run-rate and gross-to-net dynamics
- · Quarterly YUTREPIA script trends and payer coverage updates through 2026
- · L606 Phase 3 enrollment milestones and interim data readouts
- · Potential short squeeze: 13.9% short float and 6.05 days to cover could amplify moves on positive litigation or commercial news
- · Label expansion study initiations (PH-COPD, IPF, PPF) broadening the addressable market
Key risks
- · Adverse outcome in UTHR litigation removing YUTREPIA from market
- · Slower-than-modeled YUTREPIA uptake due to payer pushback or Tyvaso DPI entrenchment
- · HCR covenant breach triggering acceleration of revenue-interest obligations
- · Single-source supplier disruption halting YUTREPIA production
- · Need for additional dilutive financing given negative FCF and modest cash cushion
- · Multiple compression if growth decelerates from the explosive 2025 base
What to watch
- · August 12, 2026 earnings — YUTREPIA revenue run-rate, gross-to-net, and gross margin progression
- · Any procedural updates or rulings in the United Therapeutics 505(b)(2) litigation
- · Key technical levels: 52-week high resistance at $73.22, support near analyst mean of $66
- · Insider Form 4 filings — whether selling pressure continues at these levels
- · Short interest trajectory and any squeeze setup ahead of binary catalysts
- · HCR financing agreement amendments or covenant disclosures in upcoming filings
Key metrics
Price target rationale
Base case ~$68 assumes successful litigation defense and continued YUTREPIA ramp, applying ~15x forward earnings on improving estimates — broadly in line with Street. Bull case ~$95 reflects clean litigation outcome, strong script momentum, and short-squeeze dynamics with multiple expansion. Bear case ~$20 reflects an adverse UTHR ruling collapsing the YUTREPIA thesis, leaving residual L606 optionality and the Treprostinil Injection profit share.
On Wall Street's view (mixed): The $66.13 consensus target sits ~7% below the current $71 price, implying limited upside, and we agree the risk/reward is balanced — UTHR litigation overhang and stretched multiples offset the genuine commercial momentum and forward-P/E support.
Latest filing (10-K)
Liquidia just launched YUTREPIA in June 2025 into a 100,000+ patient PAH/PH-ILD market with a best-in-class inhaled treprostinil profile, but an existential United Therapeutics lawsuit seeking to pull the drug's approval hangs over the entire investment thesis.
Liquidia Corporation is a biopharmaceutical company focused on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It generates revenue from two sources: direct sales of its own FDA-approved inhaled dry powder treprostinil product YUTREPIA (launched June 2025), and a profit-sharing arrangement with Sandoz on generic injectable treprostinil (Treprostinil Injection) under a promotion agreement. The company uses its proprietary PRINT particle engineering technology to manufacture precisely engineered drug particles for enhanced pulmonary delivery.
What the news says · neutral
The dominant storyline for LQDA centers on new YUTREPIA data presented at PHA 2026, which has generated mixed valuation signals — one analysis flags the stock as potentially 63% overvalued post-conference, while another suggests a recent 5% pullback has made it undervalued. Insider activity is a notable concern, with a director selling ~$14M in common stock and the HR chief offloading ~25K shares under a 10b5-1 plan, alongside a Canaan entity selling 196K shares. On the positive side, Q1 earnings beat expectations, the stock carries strong technical momentum scores, and shareholders broadly backed management at the annual meeting. The conflicting valuation reads and meaningful insider/institutional selling temper what is otherwise a constructive fundamental and technical backdrop.
This analysis is from Jun 21, 2026. Markets move. Get the current read on LQDA and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.